Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Asks METI to Exclude Drug Production Facilities from Planned Electricity Outages
April 11, 2011
- NICE Recommends Aricept for Mild AD
April 11, 2011
- Seikagaku Withdraws PMA for Additional Indication of Supartz in the US
April 11, 2011
- Earthquake Disrupts Production of Some Raw Materials
April 11, 2011
- PMAT, OPMA Petition MREAC on Pass/Fail Criteria for MR Exam
April 11, 2011
- Korosho Requires Revision of Package Insert for Hib Vaccine, Pneumococcal Vaccines
April 11, 2011
- Production, Shipment of Sublood to Resume in Mid-April: Fuso
April 11, 2011
- RAD-AR Completes Patient Database on Antihyperlipidemics
April 11, 2011
- Gov't-Private Sector Dialogue Postponed due to Earthquake
April 11, 2011
- MTPC Aims to Resume Operations at 2 Plants in Mid-April
April 11, 2011
- ProStrakan Shareholders Accept Acquisition by Kyowa Kirin
April 11, 2011
- Shionogi Signs Agreement with Denmark on Industry-Academic Collaboration
April 11, 2011
- Some Companies Postpone April Personnel Changes due to Earthquake
April 11, 2011
- Abbott Japan Completes Acquisition of Former Solvay Pharm.
April 11, 2011
- OncoTherapy Starts PII Trial of Angiogenesis Inhibitor
April 11, 2011
- Eisai Licenses Bexarotene to Minophagen
April 11, 2011
- P&G, Teva to Combine Their OTC Businesses
April 11, 2011
- OncoTherapy Begins Recruitment for Cancer Vaccine Trial
April 11, 2011
- Eisai Enters Collaborative R&D Agreement with PRISM BioLab
April 11, 2011
- BI Japan Starts Operations
April 11, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…